Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report.
JTO Clin Res Rep
; 4(8): 100546, 2023 Aug.
Article
in En
| MEDLINE
| ID: mdl-37644967
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Language:
En
Journal:
JTO Clin Res Rep
Year:
2023
Document type:
Article
Country of publication:
United States